On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.82 USD | +3.43% | -0.41% | -14.69% |
Jun. 10 | C4 Therapeutics Appoints Ron Cooper Board Chairman | MT |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
36.91 CNY | -0.73% | -1.63% | 2.13B | ||
4.82 USD | +3.43% | -0.41% | 332M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.69% | 332M | |
+49.41% | 56.95B | |
+40.63% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.